500 million men suffer from erectile dysfunction and premature ejaculation worldwide. Dicot is developing a modern potency drug with the ambition of creating a therapeutic drug that has a longer lasting effect and fewer side effects than those found on the market today.
Dicot - the potency drug of tomorrow

Press release | 2022-11-15
Assumed to be the next generation of potency drugs
Dicot's latest study of the mechanism of action of LIB-01, shows that it differentiates from today's potency drugs.
Read More >Dicot - Naventus Healthcare Summit May 2022

Pharmaceutical Project
The aim of this year's development work is to prepare LIB-01 for clinical studies next year.
Read More >The ambition with LIB-01
- Longer duration
- Effective for everyone
- Minimal side-effects

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 867137.